Baseline characteristics of patients in the randomized study to investigate the efficacy and safety of ferric carboxymaltose as treatment for heart failure with iron deficiency: HEART-FID trial-Reference-Cited by-同舟云学术

Baseline characteristics of patients in the randomized study to investigate the efficacy and safety of ferric carboxymaltose as treatment for heart failure with iron deficiency: HEART-FID trial

Published:2023-12 Issue: Volume:266 Page:25-31
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Harrington Josephine,Mentz Robert J.,Rockhold Frank W.,Garg Jyotsna,Butler Javed,De Pasquale Carmine G.,Ezekowitz Justin A.,Lewis Gregory D.,O'Meara Eileen,Ponikowski Piotr,Troughton Richard W.,Wong Yee Weng,Adamczyk Robert,Blackman Nicole,Hernandez Adrian F.

Funder

American Regent

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference12 articles.

1. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency;Ponikowski;Eur Heart J,2015

2. Ferric carboxymaltose in patients with heart failure and iron deficiency;Anker;N Engl J Med,2009

3. Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency;Butler;Eur J Heart Fail,2022

4. Responder analysis for improvement in 6-min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency;Anker;Eur J Heart Fail,2022

5. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial;Ponikowski;Lancet,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ferric carboxymaltose for iron deficiency in patients with heart failure: a systematic review and meta-analysis;Future Science OA;2024-07-09

2. Iron therapy for patients with iron deficiency and heart failure: a treatment strategy that is increasingly opaque;Baylor University Medical Center Proceedings;2024-03-18